Investor Guide
Life Sciences SPV Investing
How special purpose vehicles work, why early-stage life sciences deals sometimes use them, and what to check before participating in one.
A special purpose vehicle, or SPV, is a legal entity formed for one purpose: to make a single investment. Rather than each investor appearing individually on a company's cap table, the SPV appears once, and investors hold an interest in the SPV itself. It is a structure borrowed from venture investing broadly, and it shows up in life sciences deals for the same reasons it shows up everywhere else — it lets a syndicate of investors, sometimes at quite different check sizes, participate in one round without complicating the company's ownership table.
For a life sciences deal specifically, an SPV can matter a bit more than in a typical software round: early-stage biotech and medtech rounds are often capital-intensive relative to the number of individual angel checks available, and pooling capital through one vehicle can be what makes a meaningful allocation accessible to investors who would not otherwise meet a lead investor's minimum check size.
The tradeoff is a layer of structure between the investor and the company: fees, a manager making decisions on the pooled position, and terms that are worth reading carefully rather than assuming are standard. None of that makes an SPV a bad structure — it is a normal and common one — but it is worth understanding before committing capital to one.
What is a special purpose vehicle (SPV)?
An SPV is a legal entity created to make a single investment. Investors put capital into the SPV rather than directly into the company, and the SPV holds one line on the company’s cap table on their behalf. It is a common way to let a group of investors — sometimes writing quite different check sizes — participate in one round together.
Why would a life sciences deal use an SPV instead of direct investment?
It is often the cleanest way to bring smaller checks into a round without adding dozens of individual names to a company’s cap table, which many founders and lead investors prefer to keep simple. It can also let investors access an allocation that would otherwise require a larger minimum check.
Does ChaosBio structure deals through SPVs?
It depends on the deal. Structure — direct investment, syndicate, or SPV — is decided per opportunity and explained plainly when a deal is shared, never assumed or buried in fine print.
What should an investor ask before joining an SPV?
Who manages it and makes decisions on the underlying position, what the fee and carry structure is, how updates and eventual distributions are handled, and what rights (if any) come with the SPV interest versus a direct stake. A memo that does not answer these plainly is worth asking about.
Join the network to see how specific deals are structured.
Structure is explained plainly whenever ChaosBio shares an opportunity — join the Investor Network to see it firsthand, with no obligation to invest.